- Display 45 Products per page
Published: October 1, 2007 | Price: $995.00 – $1,990.00
It can be said that pharmaceutical companies face a 'new era.' in the coming years. Old strategies will not produce the same results. A wave of generic competition is poised to affect most brands. Drug companies have had to cut research budgets, leading to a dearth of new products on the market. This means there is very little margin for error in the pricing decision. Drug pricing is one of the key levers that determine the profitability of a drug...Published: October 1, 2007 | Price: $995.00 – $5,000.00
In five years, Kalorama Information believes that given the role of pharmacists currently and the demands of the US healthcare system, pharmacists will be prescribing in at least six states in five years, creating a trend that will spread to many other states in following years. The state of Florida allows some independing prescribing off an approved list, and many states allow prescription choice from a physicians diagnosis. The cost of copays and the time spent on doctor visits will...Published: November 1, 2007 | Price: $1,500.00 – $7,000.00
Offshoring of clinical trials is increasing as companies in the U.S. are finding challenges in clinical trial research ranging from cost, patient recruitment, patient compliance during participation, qualified professionals, new clinical trial patients, and other problems. This provides an opportunity for BRIC countries and other developing regions to grab a piece of the clinical trial market. Countries such as India and China have a vast population who are interested in taking part in clinical trial research, and these regions can...Published: December 1, 2007 | Price: $995.00 – $7,990.00
Kalorama's 2nd edition of The World Cardiovascular Drugs Market, in its 2nd edition, will steer marketers through the sheer size and diversity of the current market and the potential of new products that will make this therapeutic category among the most competitive of prescription drug segments. Analyst Mary Ann Crandall considers both the exisiting products and the pipeline in this comprehensive market study. The following market segments are covered: Cardiac Glycosides and Positive Inotropic Agents Antihypertensive Agents (ACE Inhibitors, Angiotensin...Published: January 1, 2008 | Price: $995.00 – $7,000.00
Rheumatoid arthritis and lupus belong to a number of autoimmune diseases affecting the musculoskeletal system, multisystemic tissue, and connective tissues. Although a range of autoimmune conditions carry a low prevalence, combined these diseases amount to a growing medical and economic burden. Additionally, autoimmune diseases are accounting for a growing cause of disability in the United States, Europe and worldwide. Kalorama's Worldwide Market for Rheumatoid Arthritis and Lupus Treatments (Autoimmune Disease Markets) is the most comprehensive look at the markets for...Published: January 1, 2008 | Price: $995.00 – $7,990.00
Although much of medicine is focused on the increased aging of the population, children still represent the bulk the dependent population worldwide. Important regulatory factors are at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. Pediatric Drugs, the...Published: January 1, 2008 | Price: $4,200.00 – $7,800.00
One of Kalorama's best-selling market research reports, this report provides the reader with a complete analysis of the domestic and international markets for pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatological Drugs is the sixth time Kalorama Information has comprehensively studied the dermatology markets. Kalorama has completely re-evaluated the market from the ground up, and in addition to the usual primary research (interviews) of industry participants, clinicians, and regulators, we also conducted scores...Published: February 1, 2008 | Price: $895.00 – $6,990.00
Congestive heart failure is an increasingly important cause of cardiovascular morbidity and mortality. It is the number one cause of hospitalization among individuals aged 65 and over. The United States Medicare system pays out more for the care of congestive heart failure than it does for all forms of cancer combined. While this is a challenge for the US healthcare system, it indicates a strong market opportunity for pharmaceutical companies involved in CHF treatment. Kalorama Information's Congestive Heart Failure, Major...Published: February 1, 2008 | Price: $995.00 – $7,990.00
Pharmaceutical excipients are substances, other than the pharmacologically active drug or prodrug, which are included in the manufacturing process or are contained in the finished pharmaceutical product dosage form. Excipients provide enhanced functionality to the pharmaceuticals, aid the innovations in the drug development and help improve patent life as well. Excipients make the products more functional at a lower cost, a benefit much desired by the pharmaceutical industry that is inundated with pressures to reduce costs. All in all, excipients...Published: March 1, 2008 | Price: $995.00 – $3,990.00
Pharmaceutical manufacturers are utilizing new RIFD technologies to deal with multiple challenges they face in the manufacturing process. This Kalorama Information report discussions the solutions available, and covers the opportunities available to technology companies to provide services to this sector. Full coverage of the market for RFID technologies in pharmaceutical manufacturing operations is provided, including. Explanation of RFID Technologies Cost Savings from Implementation Total Market for RFID Technologies in Pharma Manufacturing Market Forecasts Major Companies Involved in RFID and...Published: March 15, 2008 | Price: $6,995.00 – $13,990.00
Pharmaceutical marketers will face a challenging time in 2008 by all reports. Understanding the dynamics of the market can assist in better planning and strategy. This Kalorama Information Report Bundle combines 5 of the most important topics for those in the pharmaceutical industry in a strategic planning, business development or marketing. Grouped together, this report reprsents over 60% off the individual report price. Retail Clinics These entities may change how America gets healthcare, and may become important outlets for pharmaceutical...Published: April 1, 2008 | Price: $995.00 – $7,000.00
In one sense, the opportunity for follow-on proteins is as good as ever. Some of the biggest-selling biologics developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, have lost patent protection or are set to lose patent protection in the US in 2007 and beyond. But there are also regulatory challenges to marketing follow-on biologics in the U.S. that companies will need to navigate to prosper. In this report, Biogenerics:...Published: April 1, 2008 | Price: $995.00 – $7,990.00
Generics, so long the force that has shaken up the branded pharmaceutical industry, is now facing its own challenges as an industry. While growth indications are strong, there are challenges for generic companies. In the next two years, consolidation will most likely rise; the sector is expected to be rocked by increased competition from companies in Eastern Europe, India and China, as well as brand name companies seeking to protect their franchises by moving into generics. Kalorama Information's World Market...Published: April 1, 2008 | Price: $995.00 – $8,200.00
Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has in 2007 and 2008. Since Kalorama Information last updated Kalorama Information's The World Market for Vaccines in the first quarter of last year, new products and better than expected profits have transformed the vaccine marketplace. Approvals that have been granted for products such as RotaTeq, Pentacel, Adacel and Zostavax and FluMist are now impacting the market. The launch and execution of the first...Published: April 1, 2008 | Price: $500.00 – $3,990.00
Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life. Kalorama Information's The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the US market for prescription drugs likely to switch in the...Published: May 1, 2008 | Price: $995.00 – $6,400.00
Over-the-counter (OTC) drugs are well situated to capitalize on worldwide economic conditions. Customers in the US and in the world under time constraints and tight budgets prefer OTC and are opting to self-medicate where possible. Developing and petro-rich nations are pushing world demand for pharmaceuticals. Pharmacists are favoring OTCs, and are a driving force behind a new class of 'behind the counter' (BTC) drugs. The aging of the population and an increase in medical conditions generally continues to bode well...Published: May 1, 2008 | Price: $3,500.00 – $7,000.00
2008 has seen no decrease in the opportunities available for outsourcing drug discovery, for a number of reasons. New technologies increase the number of targets and accelerate the identification of active compounds. There is increasing pressure to develop new lead compounds due to the near-term loss of patent protection for many drug product. And there is also pressure to reduce the time spent in drug discovery and to bring drugs to market sooner, as well as the ever-present cost considerations....Published: July 1, 2008 | Price: $500.00 – $7,000.00
Pharmaceutical markets in Brazil, Russia, India and China rank among the top twenty markets in the world with the potential to move up in ranking rather quickly. (China’s pharmaceutical market, for instance, is expected to show double-digit growth over the next five years.) Developing regions and petro-rich nations will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. Kalorama's Pharmaceutical Markets in Brazil, Russia, India and China (BRIC nations) takes a...Published: August 1, 2008 | Price: $1,500.00 – $4,995.00
Alzheimer’s Disease is the most common cause of dementia, constituting 60% to 70% of all cases, and the risk with the disease doubles every 5 years after age 65. Incidence of the disease is increasing, and the resulting attention given to Alzheimer's Disease has encouraged development of new treatments. There is an opportunity for pharmaceutical companies to compete in this market, as Kalorama analyst Melissa Elder outlines in this study. This report includes incidence of Alzheimer’s disease worldwide with information...Published: October 1, 2008 | Price: $2,995.00 – $6,995.00
The strategic concept of HIV/AIDS diagnosis and therapy is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS diagnostics and therapeutics, companies must think on a global basis. In addition to the basic pathology and complications of HIV/AIDS, there are primarily three focal points for the development of strategy in this area: potential market, epidemiology (HIV/AIDS patient trends) and technology. In his report HIV Markets for...Published: October 1, 2008 | Price: $3,500.00 – $7,000.00
Driven by mounting market pressures, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry. Kalorama Information's Outsourcing in Drug Development is the third edition of this study of the drivers for outsourcing drug development, the companies involved in this market and the opportunity for revenues. Part of the CMO Market Series,...Published: November 1, 2008 | Price: $3,995.00 – $7,990.00
It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products. There are several promising vaccines: the propholactic Gardasil has created a pathway for new vaccine products. M-Vax, Ocon-Vax in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many of the products with potential approval status over the coming...Published: November 1, 2008 | Price: $995.00 – $1,990.00
At present the Middle East region constitutes as small percent of global pharmaceutical sales. However, ever-increasing populations and governmental healthcare reforms are likely to increase demand. These markets will be essential for pharmaceuticals companies exploring new opportunities for growth. Developing regions will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. This Kalorama Information report, Pharmaceutical Markets in the Middle East (Opportunities, Key Players, Trends) takes a thorough look at the...Published: November 1, 2008 | Price: $995.00 – $3,000.00
Smoking cessation is among the most dynamic pharmaceutical markets, and one that is expected to grow despite economic conditions. More than 5 million deaths are attributed to nicotine each year. This has encouraged public health entities to pursue smoking cessation, and has driven development of smoking cessation products, both prescription and over the counter. The arrival of Chantix/Champix and its unique marketing strategy and a robust pipeline bodes well for growth in this pharmaceutical segment. This report, Smoking Cessation: World...Published: November 1, 2008 | Price: $195.00 – $995.00
Often what separates successful marketing from bad is good competitive intelligence. This is true in life sciences as much as other industries. Many companies approach CI in a way that is unplanned, indirect and harmful to their business. But how does one know if they are conducting their company's CI in the best way? If you are trying to determine how to use competitive intelligence better, if you are attempting to judge your efforts compared to companies that have been...Published: January 1, 2009 | Price: $995.00 – $7,000.00
This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing of prescription drugs and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. A major factor driving the upward trend in the number of manufacturing projects being outsourced is that specialized production, i.e., sterile manufacturing, biopharmaceutical manufacturing and specialized processes, such as chiral chemistry and improvements in catalyst activity, is often not included in the...Published: January 1, 2009 | Price: $3,500.00 – $7,000.00
A nosocomial, or hospital-acquired, infection is a new infection that is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, This type of infection is also known as a hospital-acquired infection (or more generically healthcare-associated infections). Marketing planners in the pharmaceutical or diagnostic industries should have an understanding of the market impact of nosocomial infections, as it will be an important consideration in these markets into the near future. This report. Hospital Acquired...Published: January 1, 2009 | Price: $995.00 – $1,990.00
The pharmaceutical market in Russia ranks among the top twenty markets in the world with the potential to move up in ranking rather quickly. This market will be one of several that major pharmaceutical companies are exploring for new opportunities for growth. Reliance on commodity prices makes Russia's economy and government spending on healthcare variable, but awareness of healthcare issues, especially among the younger population, and a willingness to spend personal funds on healthcare will drive Russian markets. For the...Published: February 1, 2009 | Price: $995.00 – $5,990.00
Women’s health encompasses all different areas of medicine and it would be a monumental task to address all of the areas that affect women. This report will concentrate on disorders that affect the female reproductive system and other disorders where there is at least a 70% preponderance of women affected by the disorder. The worldwide prescription drug market for women’s health consists of total manufacturers’ revenues from the following product categories: Autoimmune diseases Cancer Gynecological and Sexually Transmitted Diseases Hormones...Published: February 1, 2009 | Price: $3,995.00 – $7,590.00
This Kalorama Information report - Clinical Nutrition - focuses on three primary segments of essential medical nutrition: Infant Nutrition: (Milk-based, Soy-based, Special Needs such as Chronic Reflux or Gastrointestinal Discomfort) Enteral Nutrition (Standard and Fiber-containing Elemental and Semi-elemental, Specialized for Chronically Ill Patients) Parenteral Nutrition For each category, the report provides revenue data and forecasts for the most important segmentations. The report includes incidence of conditions which often require enteral or parenteral feeding, birth rates, over 65 population, and overall...Published: April 1, 2009 | Price: $995.00 – $2,590.00
The pharmaceutical market in India ranks among the top twenty markets in the world with the potential to move up in ranking rather quickly. This market will be essential for pharmaceutical companies exploring new opportunities for growth. Developing regions will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. This report Pharmaceutical Market in India provides market watchers with needed information on this growing market, including: Market Size and Forecast...Published: May 1, 2009 | Price: $995.00 – $7,000.00
While many areas of the pharmaceutical industry will suffer from current economic conditions worldwide, sales of over the counter drugs are widely anticipated to grow as consumers seek cheaper alternatives. Manufacturers are expected to switch prescription drugs to over the counter status where possible. In the early part of this decade there was a delcine in Rx to switches, since 2006 there has been a number of uses of this tactic to extend revenue of pharmaceutical products. In Kalorama Information's...Published: June 1, 2009 | Price: $3,995.00 – $7,990.00
The global market for human vaccines has experienced strong growth through 2008 and this is expected to continue through the forecast period. Growth will be fueled by new product introductions and rising usage in all regions. This report, Vaccines 2009: Key Players, and Critical Trends in a Fast-Changing Industry), examines the market for vaccines used in humans to previous various types of disease. Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are...Published: July 1, 2000 | Price: $995.00 – $5,990.00
Since our last edition of this report in 2007, the oral drug delivery market is the largest segment of the drug delivery market, and there’s no sign that it is slowing down. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products, and seeking to tap into the growing elderly population that requires products with a level of ease-of-use and cost benefit, it’s no surprise that the oral drug delivery market is a...Published: September 1, 2009 | Price: $2,995.00 – $5,990.00
With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets. Biopharmaceutical products are driving growth of needle-free systems; there will likely be significant increases in revenues in the vaccine arena. This report looks at that trend and reports...Published: October 1, 2009 | Price: $3,500.00 – $7,000.00
The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to them. This Kalorama Information The World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance and generic competition. The report focuses on three key segments of...Published: February 1, 2010 | Price: $1,500.00 – $8,400.00
The global market for human vaccines has experienced strong growth in the past few years, and R&D departments at many pharmaceutical companies are working on new prophylactics, some of which may see near-term marketing. What illnesses may see a vaccine option in the coming years? Which vaccines will have the most successful business model? Who are the major companies in this market, and possible new entrants? What can current vaccine success stories tell us about the future of the vaccine...Published: April 1, 2010 | Price: $3,995.00 – $7,990.00
This Kalorama Information report - The World Anesthesia Drug Market - focuses on three primary segments of anesthesia: General Anesthesia Local Anesthesia Adjunctive Therapies in Anesthesia The report covers both currently marketed and late stage development anesthesia drugs in detail. Revenues for each segment were generated using dollar and unit sales for each product. Forecasted figures were generated using a combination of projected surgical procedures, patent and exclusivity expirations, pricing trends, new developments and other factors. The report includes statistical...Published: April 1, 2010 | Price: $3,900.00 – $7,800.00
This Kalorama Information report, Worldwide Market for Prescription Dermatological Drugs details the various categories of prescription dermatological drugs, describes the global market and identifies major market factors that may help to shape the market for treatments in the future. Full Coverage of Nine Prescription Dermatological Drug SegmentsThe global market for prescription dermatology drugs includes products in the following categories: Prescription Acne and Rosacea Drugs (Benzoyl, Retinoids, Antibiotics, Other) Prescription Antiaging and Photodamage Drugs (Keratolytics, Moisturizers, Retinoids,...Published: May 1, 2010 | Price: $500.00 – $2,400.00
The H1N1 flu epidemic created a public health emergency in 2009. It also created an opportunity for vaccine manufacturers to demonstrate that working with governments of the US and countries around the world, they could manufacture and distribute a vaccine for the virus strain that may have had an impact in reducing cases and deaths. Who were the companies that performed best in this market? How did goverment contracts play out? Most importantly, what are lessons for future pandemic and...Published: May 1, 2010 | Price: $3,995.00 – $7,990.00
Over-the-Counter (OTC) drugs are non-prescription drugs sold to consumers at pharmacies, convenience and grocery stores. These drugs include pain relievers, cough and cold remedies, sleeping aids, antifungals, and other products approved for use as a self-medication product. There has been a particular focus in the pharmaceutical industry on OTC drugs, and in several market research reports over the past decade, Kalorama Information has covered the strategies pharmaceutical companies are using in the OTC market. This report, The Worldwide Over the...Published: June 1, 2010 | Price: $3,995.00 – $7,990.00
Kalorama Information's Outsourcing in Drug Discovery offers unparalleled discussion of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers is covered in detail. The report also provides profiles of 22 suppliers, representative of those active in this market. Segments covered in this report include: Chemistry Services Building Blocks Compound Synthesis Libraries Process Research Other Services Biology Services Protein...Published: July 1, 2010 | Price: $995.00 – $1,990.00
What Will The Pharmaceutical Market Look Like in the Next Five Years?In this report, Kalorama has analyzed the late stage R&D pipeline of the 50 top companies in pharmaceuticals -- the companies that produce the lion's share of industry revenues. While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a...Published: August 1, 2010 | Price: $3,995.00 – $7,990.00
Vaccines have been one of the faster growing areas of the pharmaceutical industry, and during a troubling series of years, they have been the superstars of many companies' portfolios. They've also attracted the attention of insurance companies, retail outlets and the media. The global market for vaccines experienced strong growth through 2009 and this is expected to continue through the forecast period. Growth is being fueled by new product introductions and rising usage in all regions. Kalorama Information has been...Published: September 1, 2010 | Price: $1,500.00 – $3,000.00
Kalorama has been researching and examining the development of cancer vaccines for seven years. In April 2010, the cancer vaccine market experienced one of the biggest achievements in the therapeutic vaccine treatment of cancer—the approval of the prostate cancer vaccine PROVENGE (TM). This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was merely a speculative area just one decade ago. Even with achievements for some companies, numerous vaccines with apparently strong...